ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
13/111
Maximize
existing
brands
Enhance
organizational
agility and
collaboration
invest to grow
Lundbeck
Maintain
focus on
profitability
Expand and
Rebuild
pipeline
Expand
operating
space
Figure 1: Lundbeck's strategic imperatives
In the future, we will work with even more agility and
collaboration across geographies, simplifying our processes and
accelerating our ability to test and learn for faster, higher-quality
decision making. This will fully leverage our diverse talent,
knowledge and skillsets so that we can pursue solving
some of the biggest brain disease challenges with the greatest
patient reward.
EXPAND AND INVEST TO GROW: OUR STRATEGIC
IMPERATIVES
Our strategic imperatives guide us towards reaching our
objective to expand and invest to grow.
Maximize existing brands
Our strategic brands continue to show solid growth, both in
volume and value, across all regions. At the same time, several
of our mature brands have shown remarkable resiliency. Our
commercial teams continue to accelerate our efforts in growing
our mature and strategic brands across more geographies,
thereby maximizing our existing brands to drive growth in the
coming years.
Our strategic brands
BrintellixⓇ/TrintellixⓇ is a prescription medication used to treat
major depressive disorder (MDD). The brand delivered solid
growth in 2021 despite the flattening in total prescriptions of
MDD medications in the U.S. during the pandemic.
RexultiⓇ/RxultiⓇ is a prescription medication used as an
adjunctive therapy to antidepressants for the treatment
of MDD. We will continue to maximize this medication with
launches in hopefully six additional markets in 2022.
Abilify MaintenaⓇ is one of the most prescribed long
acting injectable treatments for patients with schizophrenia. In
some European countries it is the market leader.
VyeptiⓇ is an infusion treatment for the prevention of migraine in
adults. This is our newest strategic brand, launched in the U.S.
in April 2020.
We will continue to expand our geographical reach with
approval in additional countries - in 2021 it was approved for
use in Australia, Canada, the U.A.E., Kuwait, Switzerland and
Singapore.
Our mature brands
Our portfolio of mature brands is large. In the U.S., NortheraⓇ,
OnfiⓇ, SabrilⓇ and Xenazine® are declining after the initial loss to
generics. The larger group of mature brands is remarkably
resilient having high levels of trust and brand recognition in
many markets around the world. And some of the products show
continued growth, for example CipralexⓇ/LexaproⓇ.
We continue our strong partnerships with Otsuka and Takeda
Pharmaceutical Company Limited (Takeda) to engage
healthcare professionals treating a broad range of psychiatric
diseases, with keen commercial execution against our portfolio
of strategic and mature brands.
In the coming years, we will further strengthen and reinforce our
field force ensuring that they have the digital tools and
capabilities needed to help them to expand their networks and
collaborate even better with patients and customers.
We continue to ensure patients receive the full benefit of our
medicines through continued clinical activities, life cycle
management programs, proactive patient safety efforts, medical
activities and value positioning, and also through advocacy
efforts.
Expand operating space
We expanded our operating space through the acquisitions of
Alder and Abide in 2019, which have given us the platforms
needed to expand our areas of focus in neuroscience towards
targeted indication groups of niche and rare neurology and
psychiatry. Furthermore, we continue to invest in maximizing our
strategic brand franchises BrintellixⓇ/Trintellix®, RexultiⓇ/RxultiⓇ,
Abilify MaintenaⓇ and VyeptiⓇ, and we are continuously
expanding our existing portfolio of medicines into new markets
and additional indications.View entire presentation